CNS Drug Delivery Methods

Why Direct CNS Delivery?

The blood-brain barrier (BBB) presents one of the most significant challenges in CNS drug development. This highly selective semipermeable border prevents most systemically administered therapeutics from reaching the central nervous system at pharmacologically relevant concentrations. While the BBB serves a critical protective function, it also means that many promising drug candidates for neurological diseases fail to achieve adequate CNS exposure through conventional routes of administration.

Direct delivery into the cerebrospinal fluid (CSF) or brain parenchyma bypasses the blood-brain barrier entirely, offering several compelling advantages for certain therapeutic applications:

Enhanced CNS exposure — achieve therapeutic concentrations impossible with systemic dosing

Reduced systemic exposure — minimize peripheral side effects and toxicity

Lower doses required — reduce manufacturing costs for expensive biologics

Global CNS distribution — CSF circulation delivers drug throughout the neuraxis

Enable large molecule delivery — proteins, oligonucleotides, and gene therapies can access CNS

Direct CNS delivery has become particularly important for the growing pipeline of gene therapies, antisense oligonucleotides, and other large molecule therapeutics targeting neurological conditions including spinal muscular atrophy, Huntington's disease, ALS, and various lysosomal storage disorders affecting the CNS.

CNS Delivery Methods Overview

Several anatomical routes provide access to the CSF and CNS parenchyma. The choice of delivery method depends on the therapeutic target, required distribution pattern, dosing frequency, and translational relevance to the intended clinical application.

Intrathecal (IT)

Delivery into the lumbar subarachnoid space, providing access to the spinal CSF with rostral distribution toward the brain.

Best for: Spinal cord targets, global CNS distribution with spinal emphasis

Intracerebroventricular (ICV)

Direct injection into the lateral ventricles of the brain, providing immediate access to ventricular CSF.

Best for: Brain targets, periventricular distribution

Intracisterna Magna (ICM)

Delivery into the cisterna magna at the base of the skull, accessing CSF at the brainstem level.

Best for: Brainstem, cerebellum, broad CNS distribution

Intrathecal Delivery

Intrathecal (IT) administration delivers therapeutics directly into the subarachnoid space surrounding the spinal cord. This is the most clinically established route for CNS drug delivery, with approved therapies including nusinersen (Spinraza) for spinal muscular atrophy and ziconotide (Prialt) for chronic pain.

Percutaneous vs. Surgical Approaches

Intrathecal delivery can be accomplished through percutaneous injection or via surgically implanted catheters. Each approach has distinct advantages and limitations for preclinical studies.

Percutaneous intrathecal injection involves inserting a needle through the skin and intervertebral space into the subarachnoid space, similar to a lumbar puncture. While less invasive, this approach carries risk that the needle lumen may not be fully intrathecal — some test article may be delivered subdurally or even epidurally, leading to variable and unpredictable CNS exposure.

Technical Consideration: Percutaneous IT dosing without direct visualization carries inherent uncertainty about needle placement. For studies requiring precise, reproducible CNS delivery, surgical approaches provide greater confidence in accurate intrathecal administration.

Surgical cutdown with direct visualization involves making a small incision to expose the dura mater directly. This allows the surgeon to visualize the dural puncture and confirm that the needle or catheter enters the subarachnoid space. This technique provides much greater precision and confidence in delivery location.

Catheterization Techniques

For repeat-dose studies, indwelling intrathecal catheters offer significant advantages over repeated percutaneous injections. After surgical cutdown, a catheter can be introduced into the intrathecal space and advanced to the desired position.

Common catheter tip positions include:

Lumbar positioning (30-40mm advancement) — catheter tip remains in the lumbar region, suitable for spinal cord-focused studies
Thoracic positioning — catheter advanced to mid-thoracic level for broader spinal distribution
Cisternal positioning — catheter tip advanced to the level of the cisterna magna (L1 in NHP), providing distribution similar to ICM delivery

Catheter position can be confirmed using fluoroscopy during placement, with contrast injection to verify intrathecal location and flow.

                                Best Practice: For chronic studies, exteriorized catheters connected to subcutaneous access ports allow repeated dosing without anesthesia. The port is accessed percutaneously for each dose, reducing animal stress and improving dosing consistency.
                            

Intracerebroventricular (ICV) Administration

ICV delivery places therapeutics directly into the lateral ventricles of the brain. From the ventricles, drug distributes through CSF flow into the third ventricle, fourth ventricle, and eventually the subarachnoid space surrounding the brain and spinal cord.

Surgical Technique

ICV access requires a craniotomy or burr hole through the skull, followed by insertion of a cannula or catheter through the brain parenchyma into the lateral ventricle. Stereotactic coordinates guide accurate placement, with positioning confirmed by CSF flow through the cannula.

For repeat-dose studies, an indwelling cannula or catheter is typically connected to a subcutaneous reservoir (such as an Ommaya reservoir in clinical applications, or analogous devices in preclinical models). This allows repeated ventricular access without additional surgery.

Distribution Characteristics

ICV delivery provides excellent distribution to periventricular brain regions and structures adjacent to CSF spaces. However, penetration into deep brain parenchyma may be limited, as drug must diffuse from CSF into tissue against the bulk flow of interstitial fluid toward the ventricles.

Advantages

Direct brain access, bypassing spinal route

Good periventricular distribution

Clinically translatable (Ommaya reservoir)

Established technique across species

Limitations

Requires craniotomy/burr hole

Needle track through brain parenchyma

Limited deep parenchymal penetration

Risk of hemorrhage, infection

Intracisterna Magna (ICM) Administration

The cisterna magna is a CSF-filled space located between the cerebellum and the medulla oblongata, accessible from the back of the head at the atlanto-occipital junction. ICM delivery has gained increasing popularity in preclinical CNS drug development, particularly for gene therapy and large molecule programs.

Anatomical Considerations

The cisterna magna is the largest of the subarachnoid cisterns, providing a relatively spacious target for injection. Its location at the base of the brain means that drug delivered here has relatively short distances to travel to reach both brain and spinal cord tissues.

Technique

ICM injection can be performed percutaneously or with surgical exposure. The percutaneous approach uses anatomical landmarks and imaging guidance (fluoroscopy or CT) to advance a needle through the atlanto-occipital membrane into the cisterna magna. CSF flow confirms correct positioning.

For non-human primate studies, the procedure typically involves positioning the animal with the head flexed, identifying the atlanto-occipital junction, and carefully advancing a spinal needle until CSF is obtained.

Distribution Advantages

ICM delivery often provides superior global CNS distribution compared to lumbar intrathecal injection. Drug deposited in the cisterna magna distributes both rostrally (toward the brain via basal cisterns) and caudally (down the spinal subarachnoid space).

                                Research Finding: Studies comparing IT lumbar vs. ICM delivery of AAV vectors have demonstrated significantly higher transduction in brain regions with ICM administration, making it the preferred route for many CNS gene therapy programs targeting both brain and spinal cord.
                            

Delivery Method Comparison

The following table summarizes key characteristics of each CNS delivery approach to help sponsors select the most appropriate method for their program:

Characteristic	Intrathecal (Lumbar)	ICV	ICM
Primary target	Spinal cord, CSF	Brain, periventricular	Brain + spinal cord
Surgical complexity	Low-moderate	High (craniotomy)	Low-moderate
Brain distribution	Moderate	Good (periventricular)	Good-excellent
Spinal distribution	Excellent	Moderate	Good
Clinical translation	Excellent (LP standard)	Good (Ommaya reservoir)	Emerging
Repeat dosing	Yes (catheter/port)	Yes (reservoir)	Limited
Risk profile	Low	Moderate-high	Low-moderate

Surgical Considerations

The quality of CNS delivery studies depends heavily on surgical technique. Key considerations include:

Direct Visualization

Whenever possible, surgical cutdown to directly visualize the dura provides the greatest confidence in accurate delivery. Blind percutaneous techniques, while less invasive, carry higher risk of extradural or subdural misplacement.

Catheter Selection

Catheter material, diameter, and tip configuration affect both placement accuracy and long-term patency. Silicone and polyurethane catheters are commonly used, with smaller diameters appropriate for rodents and larger for NHPs.

Confirmation of Placement

CSF flow, fluoroscopic imaging with contrast, or post-procedure imaging should confirm accurate catheter or needle placement before dosing. This is particularly important for IND-enabling studies where delivery accuracy directly impacts data interpretation.

Aseptic Technique

CNS infection is a serious complication that can invalidate study data and compromise animal welfare. Strict aseptic technique, appropriate antimicrobial prophylaxis, and careful wound management are essential.

Species Selection for CNS Studies

Species selection for CNS delivery studies depends on the therapeutic target, required anatomy, and regulatory expectations:

Rodents (Rats, Mice)

Useful for early proof-of-concept and biodistribution studies. ICV is straightforward with stereotactic equipment. IT delivery in rodents requires specialized technique due to small anatomy but is feasible.

Non-Human Primates

Essential for most IND-enabling CNS delivery programs due to anatomical similarity to humans. Cynomolgus macaques are most commonly used. All delivery routes (IT, ICV, ICM) are well-established with translatable anatomy.

Large Animals (Sheep, Pigs)

Occasionally used for device development or surgical technique optimization. Brain and spinal cord size approximates human anatomy, but these species are less commonly accepted for regulatory toxicology.

Regulatory Note: For biologics and gene therapies targeting human-specific sequences, NHP studies are typically required due to lack of pharmacological activity in other species. Discuss species selection with regulatory toxicologists early in program planning.

Choosing a CRO for CNS Delivery Studies

CNS drug delivery studies require specialized surgical expertise that not all preclinical CROs possess. When evaluating potential partners, consider:

Surgical Team Experience

How many CNS delivery procedures has the team performed? What is their success rate for catheter placement? Ask for references from sponsors who have conducted similar studies.

Species Capabilities

Does the facility have experience with your required species? For NHP studies, this includes appropriate housing, husbandry, and veterinary expertise.

Imaging Capabilities

Is fluoroscopy available for catheter placement confirmation? Does the facility have MRI capabilities for post-procedure verification or biodistribution studies?

Bioanalytical Integration

CSF sampling and analysis are critical for CNS PK studies. Integrated bioanalytical capabilities improve sample quality and reduce turnaround time.

Regulatory Experience

Has the CRO supported successful IND submissions for CNS-delivered therapeutics? Regulatory experience ensures study designs meet agency expectations.

Contents